Filana Therapeutics, Inc. (FLNA) Stock Price & Analysis
Filana Therapeutics, Inc. (FLNA) fell 0.70% to USD 1.42 as of June 10, 2026 at 02:37 UTC, according to Nexqual real-time market data.
FLNA last closed at USD 1.43; the session ranged USD 1.37–1.5 on volume of 316,786 shares. Market capitalization is $68.60M, with a 52-week range of USD 1.16–4.98 (NCM). Source: Nexqual, June 10, 2026 at 02:37 UTC.
Key Statistics (as of June 10, 2026 at 02:37 UTC)
| Price | USD 1.42 |
|---|---|
| Change | ▼ 0.70% (down) |
| Previous Close | USD 1.43 |
| Open | USD 1.44 |
| Day Range | USD 1.37 – 1.5 |
| 52-Week Range | USD 1.16 – 4.98 |
| Volume | 316,786 shares |
| Market Cap | $68.60M |
| Exchange | NCM |
Technical Analysis (FLNA)
Nexqual's technical model rates FLNA "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 02:37 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 47.84 (neutral) |
| vs SMA50 | Below (USD 1.49) |
| MACD | -0.02 (negative) |
Analyst Ratings (FLNA)
Wall Street analysts rate FLNA "Strong Buy" based on 2 analysts, with a mean price target of USD 6.5 (range USD 5–8), per Nexqual as of June 10, 2026 at 02:37 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 6.5 |
| High Target | USD 8 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (FLNA)
| Next Earnings Date | 2026-05-07 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.21 vs est -0.23 ▲ beat |
| 2025-12-31 | USD -0.26 vs est -0.3 ▲ beat |
| 2025-09-30 | USD -0.22 vs est -0.27 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:37 UTC.
Financials & Fundamentals (FLNA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -79.59% |
| Current Ratio | 2.19 |
| Total Cash | $86.57M |
| Total Debt | $0 |
| Free Cash Flow | $16.07M |
Source: Nexqual, June 10, 2026 at 02:37 UTC.
Financial Health Score (FLNA)
Nexqual rates Filana Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:37 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $87M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$30M |
| Efficiency | Critical — ROE -80%, ROA -24.9% |
Ownership (FLNA)
| Insider Ownership | +11.02% |
|---|---|
| Institutional Ownership | +28.72% |
| Shares Outstanding | 48.31M |
| Float | 47.32M |
| Short % of Float | +14.55% |
Source: Nexqual, June 10, 2026 at 02:37 UTC.
Leadership (FLNA)
Filana Therapeutics, Inc. is led by Richard Jon Barry (age 66), CEO, President & Director, per Nexqual as of June 10, 2026 at 02:37 UTC.
| CEO, President & Director | Richard Jon Barry (age 66) |
|---|---|
| Chief Financial Officer | Eric J. Schoen (age 57) |
| Chief Operating & Legal Officer | R. Christopher Cook (age 61) |
| Senior Vice President of Technology | George Thornton |
| Senior Vice President of Technical Operations | Michael Zamloot |
Major Backers & Investors (FLNA)
Notable institutional backers of Filana Therapeutics, Inc. include Marshall Wace LLP, Two Sigma Investments, LP, Shaw D.E. & Co., Inc., according to Nexqual as of June 10, 2026 at 02:37 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Marshall Wace LLP | 4.17% |
| Two Sigma Investments, LP | 4.12% |
| Shaw D.E. & Co., Inc. | 1.16% |
| Fidelity | 0.93% |
| GMT Capital Corp | 0.93% |
| Susquehanna International Group, LLP | 0.93% |
| Renaissance Technologies | 0.68% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.18% |
| BlackRock | 3.16% |
| Geode Capital | 1.23% |
Source: Nexqual, June 10, 2026 at 02:37 UTC.
From Filana Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
- Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OCGN | Ocugen, Inc. | USD 1.24 | ▼ 3.13% |
| AVXL | Anavex Life Sciences Corp. | USD 2.54 | ▼ 1.17% |
| VXRT | Vaxart, Inc. | USD 0.58 | ▼ 6.45% |
| BNGO | Bionano Genomics, Inc. | USD 1.16 | ▼ 0.85% |
| NVAX | Novavax, Inc. | USD 8.67 | ▼ 8.64% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:37 UTC. This page is informational and not investment advice.